A cost-effectiveness analysis comparing different strategies to implement noninvasive prenatal testing into a down syndrome screening program
File version
Author(s)
Whitty, JA
Ellwood, DA
Griffith University Author(s)
Primary Supervisor
Other Supervisors
Editor(s)
Date
Size
File type(s)
Location
License
Abstract
Noninvasive prenatal testing (NIPT) can analyze cell-free DNA of placental origin in maternal serum for trisomy 21. The detection rate is 99.5%, and the false-positive rate (FPR) is 0.2%. Noninvasive prenatal testing is recommended only for high-risk women after conventional screening. Noninvasive prenatal testing is deemed a screening modality, and invasive diagnostic testing is required for confirmation following a “positive” result. The present study was performed to evaluate NIPT by comparing 4 strategies examining cost-effectiveness and budget impacts for health care systems and parturients.
Journal Title
Obstetrical and Gynecological Survey
Conference Title
Book Title
Edition
Volume
70
Issue
2
Thesis Type
Degree Program
School
Publisher link
Patent number
Funder(s)
Grant identifier(s)
Rights Statement
Rights Statement
Item Access Status
Note
Access the data
Related item(s)
Subject
Paediatrics and Reproductive Medicine
Persistent link to this record
Citation
Ayres, AC; Whitty, JA; Ellwood, DA, A cost-effectiveness analysis comparing different strategies to implement noninvasive prenatal testing into a down syndrome screening program, Obstetrical and Gynecological Survey, 2015, 70 (2), pp. 63-65